

# Acute Respiratory Distress Syndrome - Pipeline Review, H2 2020

<https://marketpublishers.com/r/A7655ACCBB1EN.html>

Date: July 2020

Pages: 667

Price: US\$ 2,000.00 (Single User License)

ID: A7655ACCBB1EN

## Abstracts

Acute Respiratory Distress Syndrome - Pipeline Review, H2 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Respiratory Distress Syndrome - Pipeline Review, H2 2020, provides an overview of the Acute Respiratory Distress Syndrome (Respiratory) pipeline landscape. Acute respiratory distress syndrome (ARDS) occurs when fluid fills up the air sacs in lungs. This leads to low oxygen levels in the blood. Common causes of ARDS include sepsis, inhalation of harmful substances, severe pneumonia and head or chest injury. Signs and symptoms of ARDS include severe shortness of breath, labored and unusually rapid breathing, low blood pressure and confusion and extreme tiredness.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Respiratory Distress Syndrome - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Acute Respiratory Distress Syndrome (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Respiratory Distress Syndrome (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Acute Respiratory Distress Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules

developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 11, 28, 22, 4, 50, 16 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Acute Respiratory Distress Syndrome (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Respiratory Distress Syndrome (Respiratory).

The pipeline guide reviews pipeline therapeutics for Acute Respiratory Distress Syndrome (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Acute Respiratory Distress Syndrome (Respiratory) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Acute Respiratory Distress Syndrome (Respiratory) therapeutics based on mechanism of action (MoA), drug target,

route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Acute Respiratory Distress Syndrome (Respiratory)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Acute Respiratory Distress Syndrome (Respiratory).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Acute Respiratory Distress Syndrome (Respiratory) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Acute Respiratory Distress Syndrome - Overview

Acute Respiratory Distress Syndrome - Therapeutics Development

Acute Respiratory Distress Syndrome - Therapeutics Assessment

Acute Respiratory Distress Syndrome - Companies Involved in Therapeutics  
Development

Acute Respiratory Distress Syndrome - Drug Profiles

Acute Respiratory Distress Syndrome - Dormant Projects

Acute Respiratory Distress Syndrome - Discontinued Products

Acute Respiratory Distress Syndrome - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Acute Respiratory Distress Syndrome, H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Products under Development by Companies, H2 2020

Products under Development by Universities/Institutes, H2 2020

Number of Products by Stage and Target, H2 2020

Number of Products by Stage and Mechanism of Action, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Acute Respiratory Distress Syndrome - Pipeline by A6 Pharmaceuticals LLC, H2 2020

Acute Respiratory Distress Syndrome - Pipeline by AbbVie Inc, H2 2020

Acute Respiratory Distress Syndrome - Pipeline by Abivax SA, H2 2020

Acute Respiratory Distress Syndrome - Pipeline by Aerogen Ltd, H2 2020

Acute Respiratory Distress Syndrome - Pipeline by Aerpio Pharmaceuticals Inc, H2 2020

Acute Respiratory Distress Syndrome - Pipeline by Akebia Therapeutics Inc, H2 2020

Acute Respiratory Distress Syndrome - Pipeline by Alexion Pharmaceuticals Inc, H2 2020

Acute Respiratory Distress Syndrome - Pipeline by Algernon Pharmaceuticals Inc, H2 2020

Acute Respiratory Distress Syndrome - Pipeline by Ampio Pharmaceuticals Inc, H2 2020

Acute Respiratory Distress Syndrome - Pipeline by Amyndas Pharmaceuticals LLC, H2 2020

Acute Respiratory Distress Syndrome - Pipeline by APEIRON Biologics AG, H2 2020

Acute Respiratory Distress Syndrome - Pipeline by Apellis Pharmaceuticals Inc, H2 2020

Acute Respiratory Distress Syndrome - Pipeline by Xfibra Inc, H2 2020

Acute Respiratory Distress Syndrome - Dormant Projects, H2 2020

Acute Respiratory Distress Syndrome - Discontinued Products, H2 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Acute Respiratory Distress Syndrome, H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products by Top 10 Targets, H2 2020

Number of Products by Stage and Top 10 Targets, H2 2020

Number of Products by Top 10 Mechanism of Actions, H2 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020

Number of Products by Top 10 Routes of Administration, H2 2020

Number of Products by Stage and Top 10 Routes of Administration, H2 2020

Number of Products by Top 10 Molecule Types, H2 2020

Number of Products by Stage and Top 10 Molecule Types, H2 2020

### COMPANIES MENTIONED

A6 Pharmaceuticals LLC

AbbVie Inc

Abivax SA

Aerogen Ltd

Aerpio Pharmaceuticals Inc

Akebia Therapeutics Inc

Alexion Pharmaceuticals Inc

Algernon Pharmaceuticals Inc

Ampio Pharmaceuticals Inc

Amyndas Pharmaceuticals LLC

APEIRON Biologics AG

Apellis Pharmaceuticals Inc

Apeptico Forschung und Entwicklung GmbH

Aptahem AB

Aqualung Therapeutics Corp

Arch Biopartners Inc

Argenx SE

Athersys Inc

Ayuviz Research Inc

Bayer AG

Baylx Inc

BeiGene Ltd  
BioCardia Inc  
Biocon Ltd  
BioMarck Pharmaceuticals Ltd  
Biophytis SA  
BioStem Technologies Inc  
Biotest AG  
Biovista Inc  
Bioxytran Inc  
Bonac Corp  
Bonus BioGroup Ltd  
BrainStorm Cell Therapeutics Inc  
CarthroniX Inc  
Ceapro Inc  
Cellenkos Inc  
Cellresearch Corp Pte Ltd  
Celularity Inc  
Cerecor Inc  
Chiesi Farmaceutici SpA  
China Grand Pharmaceutical and Healthcare Holdings Ltd  
CohBar Inc  
Commence Bio Inc  
Curacle Co Ltd  
Cynata Therapeutics Ltd  
Cytpeutics Pte Ltd  
Diffusion Pharmaceuticals Inc  
Dimerix Ltd  
Edesa Biotech Inc  
Educell doo  
Emergent BioSolutions Inc  
Emtora Biosciences  
Enzychem Lifesciences Corp  
Eunoia Biotech LLC  
EUSA Pharma (UK) Ltd  
Evgen Pharma Plc  
Exvastat Ltd  
F4 Pharma GmbH  
Faron Pharmaceuticals Oy  
FibroGenesis LLC

Foresee Pharmaceuticals Co Ltd  
Grifols SA  
Hemarina SA  
HistoCell SL  
Human Life CORD Japan Inc  
Hydra Biosciences Inc  
Iltoo Pharma  
Immune Regulation Ltd  
IMMvention Therapeutix Inc  
Implicit Bioscience Ltd  
Impression Healthcare Ltd  
Imstem Biotechnology Inc  
In2cure AB  
Insmid Inc  
IsletOne AB  
Khondrion BV  
Koligo Therapeutics Inc  
Kubota Vision Inc  
Kyorin Pharmaceutical Co Ltd  
Lamellar Biomedical Ltd  
Lattice Biologics Ltd  
Leading BioSciences Inc  
Liminal BioSciences Inc  
LTT Bio-Pharma Co Ltd  
MannKind Corp  
Matrix Biomed Inc  
Meridigen Biotech Co Ltd  
Mesoblast Ltd  
Nano Biotherapeutics Inc  
NantKwest Inc  
Neutrolis Inc  
Northern Therapeutics Inc  
Novellus Inc  
Noxopharm Ltd  
NS Pharma Inc  
Orbsen Therapeutics Ltd  
Oryzon Genomics SA  
PharmAbcine Inc  
Pharming Group NV



PhaseBio Pharmaceuticals Inc  
Pluristem Therapeutics Inc  
Predictive Biotech Inc  
R Pharm  
Relief Therapeutics Holding AG  
Restore Therapeutics LLC  
Reven Pharmaceuticals Inc  
Roivant Sciences Ltd  
Santhera Pharmaceuticals Holding AG  
Savara Inc  
SFA Therapeutics LLC  
SolAeroMed Inc  
SynAct Pharma AB  
Syndax Pharmaceuticals Inc  
Thetis Pharmaceuticals LLC  
Trevena Inc  
Vasomune Inc  
Veru Inc  
Windtree Therapeutics Inc  
Xfibra Inc

## I would like to order

Product name: Acute Respiratory Distress Syndrome - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/A7655ACCBB1EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A7655ACCBB1EN.html>